Anti-CD73 antibodies and uses thereof
Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.
1. A method of treating cancer in a patient in need thereof, comprising administering to the patient an antibody or fragment thereof of, wherein the antibody or fragment thereof has specificity to a human CD73 protein and comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 2, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 6.
2. The method of claim 1 , wherein the cancer is selected from the group consisting of bladder cancer, breast cancer, colorectal cancer, endometrial cancer, esophageal cancer, head and neck cancer, kidney cancer, leukemia, liver cancer, lung cancer, lymphoma, melanoma, pancreatic cancer, prostate cancer, and thyroid cancer.
3. The method of claim 1 , wherein the cancer is a solid tumor.
4. The method of claim 1 , further comprising administering to the patient a second cancer therapeutic agent.
5. The method of claim 4 , wherein the second cancer therapeutic agent is an immune checkpoint inhibitor.
6. The method of claim 5 , wherein the inhibitor inhibits the expression or activity of programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation protein 3 (LAG-3), or combinations thereof.
7. The method of claim 6 , wherein the inhibitor is an anti-PD-1 or anti-PD-L1 antibody.
8. The method of claim 7 , wherein the inhibitor is selected from the group consisting of pembrolizumab, nivolumab, J43, RMP1-14, atezolizumab, ipilimumab, and combinations thereof.
9. The method of claim 1 , wherein the antibody or fragment thereof is a humanized antibody.
10. The method of claim 1 , wherein the antibody or fragment thereof comprises a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7 and 9-13, or a peptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 7 and 9-13.
11. The method of claim 10 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7 or 9.
12. The method of claim 1 , wherein the antibody or fragment thereof comprises a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 15-20 and 22-24, or a peptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 8, 15-20 and 22-24.
13. The method of claim 12 , wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 8.
14. A method of treating cancer in a patient in need thereof, comprising administering to the patient an antibody or fragment thereof that has specificity to a human CD73 protein and comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 or 9 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 8.